Boston Scientific
BSX
$42.43
-5.84%
Boston Scientific is a global medical device manufacturer focused on minimally invasive technologies inserted into the body through small incisions or natural openings, spanning interventional cardiology, cardiac rhythm management, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions, with roughly 36% of sales generated outside the United States. The company is a scaled, top-tier player in the medical devices industry, competing alongside Medtronic, Abbott, and Edwards Lifesciences, and is distinguished by its breadth across both Cardiovascular and MedSurg franchises rather than a single therapeutic niche. The current investor narrative has turned sharply negative despite solid operational execution: the stock has lost more than half its value over the past year, driven by underwhelming clinical trial results disclosed in late March, a broad large-cap sell-off, and a market that has aggressively repriced the shares even as quarterly revenue continued to grow. Management is simultaneously pushing an aggressive capital deployment story, highlighted by a roughly $1.5 billion investment in MiRus's novel TAVR technology to enter the high-growth aortic stenosis market, which bulls frame as a low-risk option on a large adjacent market while bears question the price paid and the timeline to commercialization.…
BSX
Boston Scientific
$42.43
Related headlines
Investment Opinion: Should I buy BSX Today?
Rating: Hold with a constructive bias. The core thesis is that BSX is a high-quality, cash-generative medtech franchise (70.71% gross margin, $3.625 billion trailing FCF) trading at a distressed 13.53x forward PE after a sentiment-driven 55% decline, but the absence of a near-term catalyst and two recent analyst downgrades argue for patience rather than aggressive accumulation. The 28-analyst consensus is 'buy' with a mean of 1.6 and an average target of $58.00, implying roughly 27% upside, which anchors the view that the sell-off has overshot. Supporting evidence is strong on valuation and cash flow: forward PE of 13.53x versus a 15-25x peer band, PEG of 0.88, revenue growth of 7.53% YoY, operating margin expansion from 16.18% to 21.65%, and an FCF yield of about 2.6% that funded $2.0 billion of buybacks in Q2. The risks that could invalidate the thesis are a further deceleration in Cardiovascular growth below 7%, a disappointing TAVR/MiRus timeline, and continued multiple compression; the rating would upgrade to Buy if the stock holds the $41.39 low and forward EPS estimates of $4.52 remain intact through the next two quarters, and would downgrade to Sell if revenue growth falls below 5% or the low target of $44.00 is breached on rising volume. On balance, the stock is undervalued relative to its own history (PE down from 52.97x to roughly 17x) and to peers, but fairly valued to slightly cheap on forward earnings until execution confirms the trough.
Sign up to view all
BSX 12-Month Price Forecast
The forward valuation is genuinely cheap at 13.53x earnings with a PEG of 0.88, and the operating fundamentals (70.71% gross margin, $3.625 billion FCF) do not support a 55% decline, which is why the risk/reward skews positive over twelve months. However, the stock is in a confirmed downtrend at 6.7% of its range, the March trial setback has not been fully resolved, and two recent downgrades suggest the 'buy' consensus is stale, so conviction is medium rather than high. The base case (55% probability) sees a range of $44-$58 as earnings are delivered and the multiple stabilizes, with the bull case (25%) requiring a growth re-acceleration and TAVR progress. I would upgrade to bullish if the stock holds $41.39 and Q3 revenue growth exceeds 8%, and downgrade to bearish if growth falls below 6% or the low target of $44.00 is breached on volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $57.82 and implied upside of +36.3% versus the current price.
Average Target
$57.82
0 analysts
Implied Upside
+36.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $78
Analyst target range
Coverage is deep and institutional, with 28 analysts following the stock and a consensus recommendation of "buy" (recommendation mean of 1.6 on a 1-5 scale where 1 is strong buy). The average target price of $58.00 implies roughly +27% upside from the current $45.69, a wide gap that signals the sell-side views the decline as overdone relative to fundamentals. The consensus leans clearly bullish, and the estimated revenue average of $27.81 billion (range $27.20-$28.97 billion) alongside average EPS of $4.52 supports the forward valuation case. However, the institutional ratings flow shows cracks in that bullishness: Citigroup downgraded from Buy to Neutral on September 17, 2026, and Argus Research moved from Buy to Hold on July 31, 2026, while Wells Fargo has maintained Equal Weight — a pattern of recent downgrades that suggests the consensus "buy" may be stale relative to the latest sentiment. The target range of $44.00 to $78.00 is extremely wide — a 77% spread from low to high — which signals high uncertainty and low conviction rather than a tight clustering of views. The high target of $78.00 (about 71% above the current price) implicitly assumes multiple re-expansion back toward historical norms, a successful TAVR/MiRus commercialization path, and a return to double-digit growth, while the low target of $44.00 (roughly 4% below the current price) prices in continued margin pressure, competitive losses in cardiovascular, and a prolonged de-rating. Notably, the low target sits almost exactly at the current price, meaning even the most bearish analyst sees limited further downside — a constructive signal. The wide dispersion, combined with the recent downgrades, argues that the stock is a show-me story where execution on the TAVR bet and stabilization of growth will determine whether the $58 average target is achieved.
Bulls vs Bears: BSX Investment Factors
The bear case currently has stronger near-term evidence: a 55% one-year decline, a fresh 52-week low at $41.39 in October, two recent analyst downgrades, and a trial setback that has not been fully digested. The bull case rests on a forward PE of 13.53x, a PEG of 0.88, expanding margins (70.71% gross, 21.65% operating), and a $58 average target implying 27% upside, but these are valuation arguments that require a catalyst to re-rate. The single most important tension is whether the March trial disappointment and the MiRus TAVR bet represent a temporary sentiment shock or the start of durable share loss in Cardiovascular, which is two-thirds of sales; resolution of that question, likely via the next earnings print and TAVR trial milestones, will determine whether the 13.5x forward multiple is a value trap or a generational entry point.
Bullish
- Forward PE of 13.5x is deeply discounted: BSX trades at 13.53x forward EPS of $4.52 versus a trailing PE of 48.65x, a gap that implies the market is pricing a dramatic earnings step-up. Large-cap medtech peers typically command 15-25x forward earnings, so BSX sits roughly 30-45% below the sector band despite 70.71% gross margins and a 19.78% operating margin.
- Revenue growth intact at 7.5% YoY: Q2 2026 revenue of $5.442 billion rose 7.53% from $5.061 billion a year earlier, extending a consistent multi-quarter expansion from $4.663 billion in Q1 2025. The decline is a multiple-compression event, not a demand collapse, and the Cardiovascular segment at $3.624 billion (two-thirds of sales) remains the growth engine.
- Margins expanding structurally: Gross margin climbed from 67.65% in Q2 2025 to 70.71% in Q2 2026, while operating margin rose from 16.18% to 21.65% over the same period. Q4 2025 gross margin of 74.48% shows the mix can run even higher, supporting the forward earnings bridge.
- Analyst target implies 27% upside: The 28-analyst consensus is 'buy' (mean 1.6) with an average target of $58.00 versus the $45.69 price, roughly +27% upside. Even the lowest target of $44.00 sits only about 4% below the current price, suggesting limited further downside in the sell-side view.
Bearish
- Falling knife: -55% in one year: The stock is down 55.38% over twelve months and 51.76% YTD, sitting at just 6.7% of its 52-week range ($41.39-$105.65) with a -60.39% max drawdown. Buying here is a bet on stabilization, not momentum, and the 6-month change of -26.39% shows the recovery is confined to the last quarter.
- Growth decelerated below premium expectations: The 7.53% revenue growth is well below the double-digit pace that justified the prior 50x+ PE, and the March 2026 underwhelming trial results triggered a sharp repricing. The market has de-rated BSX from a premium growth multiple (52.97x PE at year-end 2025) to a value multiple (17.2x-17.4x in recent snapshots).
- Recent downgrades signal stale consensus: Citigroup cut to Neutral on September 17, 2026, and Argus moved to Hold on July 31, 2026, while Wells Fargo stays Equal Weight. The 'buy' consensus may lag reality, and the $44-$78 target range is a 77% spread that signals low conviction rather than a tight clustering of views.
- TAVR bet is unproven and costly: The roughly $1.5 billion MiRus investment is a long-dated option on aortic stenosis with no near-term revenue, and bears question the price paid and timeline to commercialization. With no dividend (payout ratio 0) and cash down to $753 million after buybacks and debt repayment, capital is being committed ahead of proof.
BSX Technical Analysis
Boston Scientific is in a severe, sustained downtrend that has erased more than half its market value over the trailing twelve months, with a 1-year price change of -55.38% and a YTD decline of -51.76%. At the current price of $45.69, the stock sits at just 6.7% of its 52-week range of $41.39 to $105.65 — a positioning that screams falling knife rather than value opportunity, and the -60.39% max drawdown confirms this is one of the deepest corrections in the large-cap medtech space. The stock is trading roughly 57% below its 52-week high, meaning any investor buying here is betting on stabilization rather than riding existing momentum. Recent momentum, however, has decoupled from the longer-term trend in a potentially constructive way: the stock is up 2.40% over the past month and 3.25% over three months, versus a 1-month decline of -1.02% for SPY, producing a positive relative strength of +3.42 over one month. That short-term outperformance against a 1-year relative strength of -68.51 suggests the selling may be exhausting and a base is forming, though the 6-month change of -26.39% shows the recovery is still nascent and confined to the last quarter. The price action since the July low near $42.63 has been choppy but higher-lows biased, with the October sequence printing $41.58 on October 7 and then rallying to $46.01 by October 22 — a roughly 10.6% bounce off the low that hints at accumulation. Technically, the $41.39 52-week low is the critical support line; a decisive break below it would signal a fresh leg lower and likely trigger momentum-driven selling, while resistance sits at the $105.65 52-week high, far out of reach, with nearer-term resistance around the $50-$52 area where the August rally stalled. The stock's beta of 0.575 is a crucial risk-management input: at roughly 42% less volatile than SPY, position sizing can be larger for the same dollar risk, but it also means the stock will not snap back as violently in a market rally — the low beta reflects a defensive, cash-generative business whose decline is idiosyncratic (trial data, sentiment) rather than market-driven, which is both a warning and an opportunity depending on whether the fundamental thesis holds.
Beta
0.57
0.57x market volatility
Max Drawdown
-60.4%
Largest decline past year
52-Week Range
$40-$106
Price range past year
Annual Return
-58.0%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -3.8% | +0.9% |
| 3m | -7.8% | +4.1% |
| 6m | -24.9% | +7.2% |
| 1y | -58.0% | +12.4% |
| ytd | -55.2% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Revenue is growing steadily, not deteriorating: Q2 2026 revenue of $5.442 billion rose 7.53% year-over-year versus $5.061 billion in Q2 2025, and the multi-quarter trajectory shows consistent expansion from $4.663 billion in Q1 2025 through $5.065 billion, $5.286 billion, $5.203 billion, and $5.442 billion in the latest quarter. The Cardiovascular segment generated $3.624 billion versus $1.818 billion for MedSurg, meaning the cardiovascular franchise — the heart of the TAVR and electrophysiology growth story — is roughly two-thirds of sales and the primary swing factor for the investment case. The growth trend is intact and modestly accelerating on a sequential basis, which makes the 55% stock decline a multiple-compression and sentiment event rather than a fundamental breakdown, though the 7.5% growth rate is below the double-digit pace investors had priced into the prior premium valuation. Profitability is robust and improving: Q2 2026 net income was $907 million on a 16.67% net margin, gross margin came in at 70.71%, and operating margin reached 21.65%, up from 16.18% operating margin in Q2 2025 and 12.91% in Q4 2024. Gross margin has expanded from 67.65% a year ago to 70.71%, and the Q1 2026 gross margin of 69.44% and Q4 2025's 74.48% show a structurally higher-margin mix, with trailing net margin of 14.38% and operating margin of 19.78% confirming the company is solidly profitable and not on a loss-narrowing path. The one blemish is the reported EPS of $0.02 in the key metrics versus quarterly diluted EPS of $0.61-$0.90 in the income statement, a discrepancy that likely reflects a data artifact or one-time charge; the forward EPS estimate of $4.52 is the cleaner profitability signal. The balance sheet is healthy: debt-to-equity of 0.51, current ratio of 1.62, and interest coverage of roughly 12.3x on Q2 data, while trailing free cash flow of $3.625 billion against a $141.2 billion market cap implies an FCF yield of about 2.6%. Q2 2026 free cash flow of $1.279 billion on $1.474 billion operating cash flow (an 86.8% conversion rate) demonstrates the business funds itself internally, and the company returned capital via $2.0 billion of stock repurchases in the quarter while still repaying $1.662 billion of debt — a shareholder-friendly allocation that also explains the cash balance decline to $753 million. ROE of 11.91% and ROA of 6.19% are respectable for a capital-intensive device maker, and with no dividend (payout ratio of 0), all cash is being reinvested into R&D ($554 million in Q2) and M&A.
Quarterly Revenue
$5.4B
2026-06
Revenue YoY Growth
+7.5%
YoY Comparison
Gross Margin
70.7%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Because Boston Scientific is profitable (Q2 2026 net income of $907 million), the PE ratio is the appropriate primary metric, and the valuation picture is genuinely bifurcated: the trailing PE of 48.65x looks expensive, but the forward PE of 13.53x is remarkably cheap for a large-cap medtech grower. That enormous gap between trailing and forward multiples implies the market expects a dramatic earnings step-up — consistent with the analyst consensus EPS estimate of $4.52 versus the depressed trailing figure — and it means the stock is either a deep value opportunity or the trailing earnings base is distorted by one-time items. On a price-to-sales basis, the 7.03x PS ratio and 3.76x EV/Sales are far more moderate than the 29.70x EV/EBITDA, which reflects heavy amortization and depreciation from the company's acquisition-heavy history. Against the medical devices sector, where large-cap peers typically trade in the 15-25x forward PE range, BSX's 13.53x forward multiple represents a meaningful discount of roughly 30-45%, and its 7.03x PS is also below the premium multiples the stock historically commanded — a discount that is only partially justified by the trial setback and growth deceleration to 7.5%. The PEG ratio of 0.88 (below 1.0) is the strongest valuation signal in the dataset, suggesting the stock is cheap relative to its expected earnings growth, and the 69.01% gross margin and 19.78% operating margin support the argument that the discount is sentiment-driven rather than quality-driven. Historically, the stock's own PE band tells the story of the collapse: the PE ratio was 52.97x at year-end 2025, 47.86x in Q3 2025, and 55.27x in Q1 2025, versus 17.21x-17.43x in the most recent Q2 2026 and Q1 2026 historical ratio snapshots — the stock is now near the very bottom of its multi-year valuation band. Similarly, the PS ratio has compressed from 26.75x at Q4 2025 and 31.96x in Q1 2025 to 11.59x in the latest Q2 2026 snapshot, and the price-to-book has fallen from 6.18x in Q3 2025 to 2.53x. This is a classic de-rating: the market has repriced BSX from a premium growth multiple to a value multiple, which either signals a durable fundamental deterioration or an overshoot that historically has been a strong entry point for high-quality medtech franchises.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~87x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the mismatch between a 7.53% revenue growth rate and a valuation that still carries premium characteristics on some metrics. EV/EBITDA of 29.70x and price-to-cash-flow of 31.13x are elevated, and the trailing PE of 48.65x versus forward PE of 13.53x implies the market is underwriting a large earnings step-up that has not yet been delivered. The balance sheet is solid (debt-to-equity 0.51, current ratio 1.62, interest coverage roughly 12.3x), but Q2 capital deployment of $2.0 billion in buybacks plus $1.662 billion of debt repayment drained cash to $753 million, leaving less cushion if the TAVR investment or trial programs require additional funding. Revenue concentration is a structural risk: Cardiovascular generated $3.624 billion versus $1.818 billion for MedSurg, so any share loss in electrophysiology or interventional cardiology hits two-thirds of the franchise directly. Market and competitive risks are dominated by the de-rating itself: the stock has fallen from a 52.97x PE at year-end 2025 to roughly 17x in recent snapshots, and further multiple compression toward the low end of the medtech range would compound the damage even if earnings hold. The beta of 0.575 means only about 42% of market moves pass through, so the decline is idiosyncratic rather than macro-driven, but that also means a market rally will not rescue the shares. Competition from Medtronic, Abbott, and Edwards Lifesciences in TAVR and electrophysiology is intensifying just as BSX commits $1.5 billion to MiRus, and the recent downgrades from Citigroup (September 17, 2026) and Argus (July 31, 2026) show sell-side conviction is eroding. The worst-case scenario is a fresh leg below the $41.39 52-week low if the next earnings print shows growth decelerating below 7% or TAVR trial data disappoints again, which would likely trigger momentum selling and a move toward the $38-$40 area, roughly -13% to -17% from $45.69. A more severe outcome, where Cardiovascular share loss proves structural and the forward EPS estimate of $4.52 is cut, could compress the stock toward the analyst low target of $44.00 and below, with the -60.39% max drawdown as a reminder that this name can lose more than half its value in a year.
FAQ
The most severe risk is company-specific: the March 2026 trial disappointment and the unproven $1.5 billion MiRus TAVR investment could prove to be durable setbacks rather than temporary shocks, and Cardiovascular is two-thirds of sales at $3.624 billion. Financial risk is moderate, with debt-to-equity of 0.51 and interest coverage near 12.3x, but cash fell to $753 million after $2.0 billion of buybacks and $1.662 billion of debt repayment in Q2, reducing the buffer for further investment. Competitive risk is high in electrophysiology and TAVR against Medtronic, Abbott, and Edwards Lifesciences, and the recent Citigroup and Argus downgrades show sentiment can deteriorate further. Macro risk is comparatively low given the 0.575 beta, but the stock's -60.39% max drawdown demonstrates that idiosyncratic risk dominates; a break below $41.39 could produce another 13-17% decline toward $38-$40.
The twelve-month forecast has three scenarios: a base case at 55% probability with a $44-$58 range as earnings of $4.52 are delivered and the forward multiple holds at 13-15x; a bull case at 25% probability with a $58-$78 range requiring growth re-acceleration above 8% and TAVR progress; and a bear case at 20% probability with a $38-$44 range if growth decelerates below 6% or the $41.39 low breaks. The base case is most likely because it requires only that the company meets current estimates and the market stops de-rating the shares, which the recent 2.40% one-month gain and positive relative strength of 3.42 versus SPY suggest is underway. The key assumption behind the base case is that forward EPS of $4.52 is not cut and that Cardiovascular growth stays near 7-8%. The wide $44-$78 analyst target range reflects genuine uncertainty, so investors should size positions for the bear case rather than the bull case.
The valuation is bifurcated: the trailing PE of 48.65x looks expensive, but the forward PE of 13.53x is cheap versus the 15-25x range typical of large-cap medtech peers, a discount of roughly 30-45%. The PEG ratio of 0.88 below 1.0 and the PS ratio of 7.03x, down from 26.75x at Q4 2025, both point to a stock that has been de-rated well below its own history. The market is paying a discount that implies skepticism about the $4.52 forward EPS estimate and the TAVR investment timeline, not a premium for growth. If the forward earnings are delivered, the stock is undervalued; if estimates are cut, the trailing multiple suggests it is not as cheap as it appears. On balance, the evidence favors undervaluation relative to history and peers, with the caveat that the forward multiple depends on an earnings step-up that has yet to be proven.
From a risk/reward perspective, BSX offers roughly 27% upside to the $58 average analyst target against limited further downside, since even the lowest target of $44.00 is only about 4% below the current $45.69 price. The valuation is undemanding at 13.53x forward earnings with a PEG of 0.88, and the business generates $3.625 billion in trailing free cash flow with a 70.71% gross margin. The biggest downside risk is a break below the $41.39 52-week low, which could extend losses toward $38-$40, and the stock is still in a confirmed downtrend with two recent analyst downgrades. It is a good buy for long-term investors comfortable with volatility and a 12-24 month horizon who want exposure to a diversified medtech franchise at a discounted multiple, but it is not a good buy for traders seeking momentum or near-term catalysts.
BSX is better suited to long-term holding than short-term trading. The company is a mature, scaled medtech franchise with 59,000 employees, $27.81 billion in estimated revenue, and a 0.575 beta that limits both upside and downside volatility, but it pays no dividend (payout ratio 0) and its earnings visibility is clouded by the TAVR investment and trial timeline. Short-term traders face a stock at 6.7% of its 52-week range with a -60.39% max drawdown and no clear catalyst before the next earnings print, making momentum strategies risky. A minimum holding period of 12-24 months is appropriate to allow the forward EPS estimate of $4.52 to be realized and for the MiRus TAVR program to show progress. Investors should monitor the $41.39 support level and Q3 revenue growth as the key checkpoints for the thesis.